Monarch Networth Capital Ltd (MNCL) was the Lead Banker to Alembic Pharmaceutical Ltd’s fund raise of Rs 7,500 Mn via Qualified Institutional Placement (QIP). Alembic Pharmaceuticals Limited is an Indian pharmaceutical major that manufactures and market’s India Formulations, International Generics, and Active Pharmaceutical Ingredients (APIs) across the globe.
Our Approach
In November 2019, Monarch Networth initiated an extensive research report for Alembic Pharmaceutical Ltd when its market capitalization stood at ₹9,000 crores. Our Research Team believed significant potential in the stock, successfully reaching out to all institutional investors. The fruition of our investment thesis became evident as the stock surged from ₹9,000 crores to ₹18,000 crores in market capitalization within a year. This success not only earned recognition from Alembic Pharma but also bolstered confidence in our capabilities. This trust was further solidified when we were chosen as a partner in their subsequent fundraising initiatives. This collaborative journey underscores our dedication to insightful research, strategic foresight, and the ability to drive positive transformations within the financial ecosystem.
Results & Key Highlights
The QIP exceeded expectations, attracting significant interest from institutional investors. Our in-depth understanding of the pharmaceutical sector enabled us to position Alembic Pharmaceutical Ltd as an attractive investment opportunity for institutional investors. The QIP garnered substantial interest, with a subscription rate of approximately 2x, attracting investments from key industry players such as Tata MF, HDFC Life, Sundaram MF, Bajaj Life, Nippon India MF.